Inozyme Pharma INZY 深 滬
已收盤 09-19 16:00:00 美东时间
5.78
-0.030
-0.52%
華盛通- 最 高6.01
- 今 開6.01
- 成交量 18.29万股
- 最 低 5.74
- 昨 收 5.81
- 總市值 3.57亿
- 52周最高 7.795
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 2.689
- 委 比 81.76%
- 總股本 6177.20万
- 歷史最高 31.65
- 量 比 0.62
- 振 幅 4.65%
- 歷史最低 0.991
- 每 手 1
- 風險率 0.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-12 19:43
快讯 | Inozyme Pharma Inc: Jefferies承担买入评级；目标价17美元，比16美元高。
Inozyme Pharma Inc : Jefferies Assumes Coverage With Buy Rating; Target Price $...
08-13 15:03
Inozyme Pharma GAAP EPS of -$0.44
Inozyme Pharma press release (NASDAQ:INZY): Q2 GAAP EPS of -$0.44. Cash, cash equivalents, and short-term investments were $144.5 million as of June 30, 2024. More on Inozyme Pharma Inozyme: Q4 Of 202...
08-06 21:29
Inozyme Pharma Q2 EPS $(0.44) Misses $(0.39) Estimate
Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 25.71 percent decrease over losses of $(0.35) per share from
08-06 20:39
Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target
Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ:INZY) with a Outperform and maintains $15 price target.
07-26 23:44
快讯 | Inozyme pharma发布的临床前数据支持Inz-701作为潜在疗法，用于影响骨健康和血管功能的广泛罕见疾病的治疗
Inozyme Pharma Publishes Preclinical Data Supporting Inz-701 as a Potential The...
07-25 20:30
Inozyme gets Fast Track status for candidate for rare calcification condition
The U.S. FDA has granted Inozyme Pharma (NASDAQ:INZY) Fast Track designation for NZ-701, its treatment of ABCC6 Deficiency. The company noted it hopes to have an agreement with regulators on a pivotal...
07-03 01:43
快讯 | Inozyme Pharma宣布Inz-701在Abcc6缺陷中获得FDA快速路径认定。
Inozyme Pharma Announces FDA Fast Track Designation for Inz-701 in Abcc6 Defici...
07-02 20:30
快讯 | Inozyme Pharma Inc -目标在年末进行Inz-701的决定性研究。
Inozyme Pharma Inc - Targets Pivotal Study for Inz-701 by Year-End
07-02 20:30
